Therapeutic uses of MAbs directed against CD20.
BACKGROUND
There are two main classes of Abs directed against the CD20 Ag that have been developed for therapeutic intent: unconjugated and radio-labeled Abs.


METHODS
The clinical results available from the large clinical trials utilizing both the unconjugated and radiolabelled Abs are summarized in this article.


CONCLUSIONS
Both of these classes of agents have shown promise in clinical trials both alone and in conjunction with conventional chemotherapy or high-dose chemotherapy and transplantation. Ongoing research with these agents will provide further evidence of the place in clinical practice for these agents.
Vose
J M
JM
University of Nebraska Medical Center, Nebraska Medical Center, Omaha 68198-7680, USA.
D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology*; D006801:Humans; D007943:Leukemia, Hairy Cell / Q000188:drug therapy; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology; D016499:Radioimmunotherapy / Q000379:methods; D000069283:Rituximab; D013921:Thrombocytopenia / Q000188:drug therapy / Q000276:immunology; D013997:Time Factors; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000069283:Rituximab